Assignment:
1. Discuss first-line treatment options for ADHD.
2. What symptoms do you treat first?
3. Also, discuss pharmacological considerations for individuals with co-morbid ADHD and tic disorder.
Student's post:
First-line treatment options for those with attention deficit/hyperactivity disorder (ADHD) vary depending on the person's age. For example, children aged 4 until their 6th birthday are recommended to have classroom interventions/modifications, psychosocial therapy, and parent training in behavior management (PTBM), which entails routine courses for parent coaching and education regarding developmental expectations, skills to manage problem behaviors, and methods to strengthen the parent-child relationship (Eom & Kim, 2024; Gabbard, 2014). Only in severe cases where behavioral interventions are ineffective in managing the child and there is significant impairment in the child's functioning can methylphenidate be considered in this age group (Wolraich et al., 2019). Once a child is at least 6 years old, first-line treatment includes not only behavioral interventions and educational modifications like Individualized Education Programs (IEPs) but also includes FDA-approved stimulant medications such as methylphenidate and amphetamine formulations (Eom & Kim, 2024). Although stimulant medications are considered the 'gold standard' for treating ADHD across the lifespan due to their strong efficacy rates, there are other nonstimulant medication options available, such as the norepinephrine reuptake inhibitor atomoxetine, and alpha-2 agonists guanfacine and clonidine, for cases in which side effects are intolerable, there are other medical/psychiatric contraindications, or when stimulants are not effective in managing ADHD symptoms (Gabbard, 2014).
The main symptoms of ADHD include inattention, hyperactivity, and impulsivity. The symptoms to be treated first should be those that are causing the most significant impairment in the person's day to day functioning, whether it be in their ability to perform at school or work, or within their interpersonal skills and ability to maintain relationships, or ability to regulate emotions. The symptoms that pose the highest safety risk and have the greatest impact on one's quality of life should be prioritized, however consideration for each person's unique history and symptom presentation is important as certain comorbid conditions, like anxiety for example, may become exacerbated by particular ADHD treatment options (Stahl, 2021).
It is approximated that 30-50% of those with Tourette's syndrome and tic disorders also have comorbid ADHD (Pringsheim et al., 2019). In a person with ADHD, it is believed that there is deficient activation of dopamine in the prefrontal cortex, which is why dopamine-enhancing medications like stimulants are effective in mediating the problem. Treating a person with a co-occurring tic disorder is complicated by the fact that it is believed that those with tic disorders experience excessive dopamine activation in the motor striatum, which is often treated with dopamine blocking agents (Stahl, 2021). Hypothetically, a person being treated with a stimulant medication for their ADHD symptoms may subsequently experience worsening tic disorder symptoms related to dopamine activation, therefore alternative ADHD medications have been recommended in these circumstances. Alpha-2 adrenergic agonist medications such as guanfacine and clonidine are the preferred options in these cases for children or adolescents, and atomoxetine for adults (Pringsheim et al., 2019).
References:
- Eom, T. H., & Kim, Y. H. (2024). Clinical practice guidelines for attention-deficit/hyperactivity disorder: recent updates. Clinical and Experimental Pediatrics, 67(1), 26-34.
- Gabbard, G. O. (2014). Gabbard's treatments of psychiatric disorders (5th ed.). American Psychiatric Publishing.
- Pringsheim, T., Okun, M. S., Müller-Vahl, K., Martino, D., Jankovic, J., Cavanna, A. E., Woods, D. W., Robinson, M., Jarvie, E., Roessner, V., Oskoui, M., Holler-Managan, Y., & Piacentini, J. (2019). Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 92(19), 896-906.
- Stahl, S. A. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
- Wolraich, M. L., Hagan Jr, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., &Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), 1-25.